Risk for secondary cancers after first-line radiation therapy for prostate cancer

There is a recognized risk for development of secondary primary cancers (SPCs) after first-line treatment with radiation therapy for localized prostate cancer. However, a new article suggests that newer forms of radiation therapy may have noticeably reduced that risk. … READ MORE …

Cancer and the media: an academic assessment

As regular readers of this blog will be aware, The “New” Prostate Cancer InfoLink is often unhappy about the “over-hyping” of certain types of scientific and medical information related to prostate cancer in the media. … READ MORE …

Cancer development and the cellular environment

For the serious student of the biological sciences, the idea that the immediate, internal, biological environment can profoundly impact the ability of any type of cell to grow and evolve is hardly new. … READ MORE …

Screening and cancer: the controversies are spreading

As we have suggested before in these reports, the question of whether mass, population-based screening for certain cancers (including prostate cancer) is really the best strategy for prevention of risk from the disease itself is a complex one. … READ MORE …

Proton beam vs. intensity-modulated RT: out on the battle lines

The relative merits of proton beam radiotherapy (PBRT) and the more commonly available intensity-modulated radiotherapy (IMRT) as forms of external beam radiation for prostate cancer are much debated … with minimal supportive evidence on either side of the debate because no comparative trial has ever been carried out. … READ MORE …

AUA report and update no. 7: April 28, 2009

In an insightful plenary presentation this morning, Dr. Larry Norton offered an explanation of cancer evolution in the individual patient based on the principles of Darwinian evolution and “natural selection .” … READ MORE …

Leonard Salz, MD, on hope and hype

Some regular readers of the cancer literature may want to see an article just published in the Journal of Clinical Oncology by Leonard Salz, MD (a world-famous colorectal cancer specialist) on the way in which language affects perceptions in the world of cancer communication.

The article basically says we all need to be more specific about how we explain things like the difference between “significant” and “statistically significant” or what we mean by “toxicity was tolerable” in a clinical trial. And Dr. Salz makes many good points that The “New” Prostate Cancer InfoLink will do its best to take to heart!

The natural remission of cancer

An article in today’s New York Times, based on an article by Zahl et al. to be published next Tuesday in the Achives of Internal Medicine (but already available on line), is about to stir up a hornets’ nest in the world of cancer research. … READ MORE …

Information about prostate cancer for Central and South Americans

Prostate Cancer International, Inc. is pleased to announce the development of yet another regional web site providing core information about prostate cancer for every country in Central and South America: El Cáncer de Próstata Latinoamérica. … READ MORE …

Thursday’s prostate cancer news: October 23, 2008

In addition to publication of the cryotherapy best practice guidance, other news today includes:

  • Information about selenium levels in blood and prostate tissues
  • An hypothesis about sex steroid-induced inflammatory events as a trigger for prostate cancer development
  • The role of free PSA in diagnosis of prostate cancer in men with a total PSA ≤ 2.5 ng/ml
  • The impact of hormone therapy on strength and musculoskeletal performance … READ MORE …

Results of our first poll: October 16-23, 2008

A total of 91 readers took our first poll (and yes, we had hoped for a few more). The results were  … READ MORE …

Now here’s a shocker for you!

According to an article from HealthDay, published in today’s Washington Post, “Doctors are missing their cues when it comes to opportunities to empathize with the plight of their cancer patients, a new study suggests.” … READ MORE …

Your Sunday prostate cancer news: September 21

The current report covers news from last Thursday through this morning. (Your editor needed a couple of personal days for some quality time!)

  • The FTC has again sought to stop certain companies from making false advertising claims about cancer cures.
  • A new center is to focus on access to prostate cancer screening and partricipation in clinical trials among African-Americans in South Carolina.
  • An “opinion piece” in the International Herald Tribune addresses lifstyle-related issues and cancer risk.
  • A new study provides 2-year data on the use of Fosamax in prevention of bone loss for men under treatment with hormone therapy for prostate cancer. … READ MORE …

New web service for the Caribbean

Effective this morning, Prostate Cancer International is pleased to announce the completion of Phase I of the development of a new web site designed to provide basic, customized information for people in every single Caribbean island nation. For additional information, please visit the Prostate Cancer Caribbean web site

Prostate cancer news update, Thursday, September 11

Today’s prostate cancer update includes information on:

  • The lack of any specific connection between prostate cancer risk and a history of sexually transmitted infection
  • A review of current issues in the management of “high risk” prostate cancer patients
  • The effect the Medicare Modernization Action on the use of orchiectomy as compared to LHRH agonist therapy
  • The impact of prostate cancer treatment and outcomes of treatment on couples … READ MORE …

Get every new post delivered to your Inbox.

Join 1,132 other followers